Aurobindo Pharma edges past Dr Reddy’s in FY26 revenue race

Aurobindo Pharma surpasses Dr Reddy's in FY26 revenue, becoming the second-largest Indian pharma company.

venerdì 22 maggio 2026 New tab

221 words~1 min read

SENSEX 75,495.00

+ 311.64

NIFTY 23,752.85

+ 98.15

CRUDEOIL 9,403.00

Other newsrooms on this story

· 3 sources

· 3 sources

Consolidated net profit in Q1 rises to ₹2,895 crore ($303.54 million) from ₹2,279 crore a year earlier

thehindubusinessline.com22 g fa

Supply disruption has cast doubt on Dr Reddy's ability to capitalise on its early lead, with brokerages warning that prolonged…

thehindubusinessline.com1 mese fa

Aurobindo Pharma posts a 25% rise in Q1 net profit to ₹1,032 crore as revenue reaches a record ₹9,150 crore on broad-based…

thehindubusinessline.com16 g fa

Citi retains its sell call with a target price of ₹1,040, and BofA retains its accumulate recommendation with a target price of…

thehindubusinessline.com1 mese fa

Aurobindo Pharma's Q1 net profit rises 25% to ₹1,032 crore, driven by strong revenue growth across its businesses.

thehindu.com16 g fa

Aurobindo Pharma reports a 2% net profit rise to ₹921 crore with total revenue growing 5.6% to ₹8,853 crore in Q4.

thehindubusinessline.com3 mesi fa